Dataset from A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults

ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel
group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected
antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to
receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an
investigator selected background regimen consisting of at least one fully active agent plus
no more than one second single agent which may or may not be active. Antiviral activity,
safety, pharmacokinetics (PK), and development of viral resistance will be evaluated.